FOLH1 and neoplasm: Another patient with a low-PSMA-expressing tumor showed an increased PSMA expression after 5 months of 160 mg enzalutamide treatment QD from 4.4 to 16.4, measured by SUV on 68Ga-PSMA-11 PET/CT [67].